0 code page views remaining today. Guest accounts are limited to 2 daily page views. Register free account to get more views.
Log in Register free account

Official Description

Hepatitis B vaccine (HepB), 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dosage, 3 dose schedule, for intramuscular use

© Copyright 2025 American Medical Association. All rights reserved.

Common Language Description

The hepatitis B vaccine (HepB) is designed to provide active, long-term immunity against hepatitis B, a serious liver infection that can lead to chronic disease, hospitalization, and even death. Unlike immune globulins, which offer short-term, passive immunity, vaccines stimulate the recipient's immune system to produce its own antibodies. This process involves exposing the immune system to altered versions of the hepatitis B virus, prompting it to recognize and remember how to combat the virus in future encounters. The HepB vaccine is particularly significant as it not only protects against the immediate effects of the virus but also mitigates the risk of long-term complications, such as hepatocellular carcinoma, making it one of the pioneering cancer vaccines in medical use. The vaccine can be derived from the blood plasma of asymptomatic carriers or synthesized through recombinant technology, where a plasmid containing the hepatitis gene is inserted into baker's yeast. This yeast is then lysed, and the components are purified to create the vaccine. The CPT® Code 90759 specifically refers to the adult 3-antigen hepatitis B vaccine, which includes the S, Pre-S1, and Pre-S2 surface antigens, administered in a three-dose schedule via intramuscular injection. It is important to note that this code solely reports the vaccine product, and the administration of the injection should be billed separately.

© Copyright 2025 Coding Ahead. All rights reserved.

1. Indications

The hepatitis B vaccine (HepB) is indicated for individuals who require protection against hepatitis B virus infection. The following conditions and circumstances warrant the administration of this vaccine:

  • High-Risk Populations Individuals who are at increased risk of exposure to hepatitis B, such as healthcare workers, individuals with multiple sexual partners, and those who inject drugs.
  • Chronic Liver Disease Patients with chronic liver conditions who may be more susceptible to the effects of hepatitis B infection.
  • Travelers Individuals traveling to regions where hepatitis B is endemic.
  • Infants Born to Infected Mothers Newborns of mothers who are hepatitis B positive should receive the vaccine to prevent transmission.

2. Procedure

The administration of the hepatitis B vaccine involves several key procedural steps to ensure proper delivery and effectiveness:

  • Step 1: Preparation Prior to administration, the vaccine should be prepared according to the manufacturer's instructions. This includes checking the expiration date, ensuring the vaccine is at the appropriate temperature, and gently shaking the vial to mix the contents if necessary.
  • Step 2: Patient Assessment The healthcare provider should assess the patient’s medical history, including any previous allergic reactions to vaccines, and confirm the need for the hepatitis B vaccine based on the indications.
  • Step 3: Site Selection The vaccine is administered intramuscularly, typically in the deltoid muscle of the upper arm for adults. The site should be cleaned with an antiseptic wipe to reduce the risk of infection.
  • Step 4: Injection Using a sterile syringe and needle, the vaccine is injected into the muscle at a 90-degree angle. Care should be taken to aspirate the syringe to ensure that the needle is not in a blood vessel before injecting the vaccine.
  • Step 5: Post-Injection Care After the injection, the site may be gently massaged to promote absorption, and the patient should be monitored for any immediate adverse reactions. Documentation of the vaccine administration, including the date, site, and lot number, should be completed in the patient's medical record.

3. Post-Procedure

Following the administration of the hepatitis B vaccine, patients are typically advised to remain in the healthcare setting for a short period to monitor for any immediate allergic reactions. Common post-injection reactions may include soreness at the injection site, mild fever, or fatigue, which usually resolve within a few days. Patients should be informed about the importance of completing the full three-dose schedule to ensure optimal immunity. Follow-up appointments should be scheduled to administer the subsequent doses, typically at 0, 1, and 6 months after the initial dose. It is also essential to educate patients on the signs of potential adverse reactions and when to seek medical attention.

Short Descr HEP B VAC 3AG 10MCG 3 DOS IM
Medium Descr HEP B VACC 3 AG 10 MCG 3 DOSE SCHED FOR IM USE
Long Descr Hepatitis B vaccine (HepB), 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dosage, 3 dose schedule, for intramuscular use
Related Drugs PREHEVBRIO
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
APC Status Indicator Influenza, Pneumococcal Pneumonia, Hepatitis B, and Covid-19 Vaccines; Monoclonal Antibody Therapy Product
ASC Payment Indicator Corneal tissue acquisition, hepatitis B vaccine; paid at reasonable cost.
Type of Service (TOS) 1 - Medical Care
Berenson-Eggers TOS (BETOS) none
MUE 1
59 Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25.
GC This service has been performed in part by a resident under the direction of a teaching physician
Date
Action
Notes
2023-01-01 Added First appearance in CodeBook.
2022-07-01 Note FDA approval granted.
2022-01-01 Added Code added. Effective upon receiving emergency Use Authorization or approval from the FDA.
Code
Description
Code
Description